Table 3.
Comparison between the baseline characteristics of the Teixeira et al. and Shouval et al.8 study populations.
| Variable | Teixeira et al. (n = 79) |
Shouval et al.8 (n = 1848) |
||
|---|---|---|---|---|
| Value | Value | |||
| Age at transplant, median in year (IQR) | 38 | (27–47) | 46 | (35–55) |
| Interval between diagnosis and transplant, median in days (IQR) | 696 | (209–753) | 236 | (166–415) |
| Diagnosis, n (%) | ||||
| AML | 54 | (68.4) | 1258 | (68.1) |
| ALL | 25 | (31.6) | 590 | (31.9) |
| Disease stage, n (%) | ||||
| CR1 | 37 | (46.9) | 966 | (60.4) |
| CR2 | 20 | (25.3) | 334 | (20.9) |
| Advanced* | 22 | (27.8) | 300 | (18.8) |
| Patient sex, n (%) | ||||
| Male | 44 | (55.4) | 1060 | (57.6) |
| Female | 35 | (44.3) | 781 | (42.4) |
| Donor Type, n (%) | ||||
| Related | 61 | (77.2) | 931 | (50.4) |
| Unrelated | 18 | (22.8) | 917 | (49.6) |
| Conditioning regimen, n (%) | ||||
| MAC | 73 | (92.4) | 1441 | (81.3) |
| RIC | 6 | (7.6) | 331 | (18.7) |
| Stem cell source, n (%) | ||||
| Bone marrow | 17 | (21.5) | 554 | (30.1) |
| Peripheral blood | 62 | (78.5) | 1285 | (69.9) |
| Karnofsky performance status, n (%) | ||||
| ≥ 80% | 76 | (96.2) | 1440 | (95.6) |
| < 80% | 3 | (3.8) | 65 | (4.4) |
| Patient CMV serostatus, n (%) | ||||
| Positive | 70 | (88.6) | 1265 | (81.4) |
| Donor- recipient CMV serostatus combination | ||||
| Both negative | 3 | (3.8) | 159 | (10.7) |
| Both positive | 57 | (72.1) | 815 | (34.5) |
| One negative/unknown and other positive | 19 | (24.1) | 514 | (34.5) |
CMV: cytomegalovirus; IQR: interquartile range; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; MAC: myeloablative conditioning (regimen); RIC: reduced intensity conditioning (regimen); CR1: first complete remission; CR2: second complete remission.
⁎
Advanced = refractory disease and > CR2.